Navigation Links
Revised: Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
Date:8/4/2009

BEIJING, Aug. 4 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE AMEX: SVA), a leading provider of vaccines in China, announced today that the clinical trial of its A/H1N1 influenza vaccine is proceeding well. All of the volunteers received their first shot of the vaccine and, during the three day observation period, the preliminary tests indicated that the A/H1N1 influenza vaccine is safe and reliable in humans.

The clinical trial began on July 22, 2009 and a total of 1,614 volunteers, including 101 elders, 706 adults, 404 juvenile and 403 children, had received the first shot of the vaccine through July 25. During the three-day observation period, none of the volunteers participating in Sinovac's clinical tests exhibited any sign of severe adverse reactions. Total adverse event rate is 11.8%, which is similar to that of seasonal influenza vaccine. The adverse events were all mild and transient. The most severe symptom was pain at the site of injection.

This clinical trial is organized by China's Center for Disease Control (CDC), and undertaken by Beijing CDC. The Ministry of Health (MOH) and State Food and Drug Administration (SFDA) are paying close attention to this clinical trial. Deputy Director General of MOH Disease Control Department, Donglou Xiao, Director of SFDA Registration Section, Wei Zhang, and other relevant experts visited the clinical trial site to observe the clinical trial. In June 2009, the Beijing municipal government(1) made its first purchase of Panflu from Sinovac, with an initial order of four million doses that are expected to be delivered by the end of September 2009.

Consistent with prior years' practices, Sinovac's seasonal influenza vaccine was released by China SFDA and commercially launched at the end of July 2009.

    (1) Sinovac's press release date
'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Revised: Othera Pharmaceuticals Appoints Dr. Frederick R. Rickles Chief Scientific Officer
2. REVISED: BrainCells Inc. Expands Series B Financing to $50 Million
3. Sinovac Announces Postponement of Annual General Meeting
4. Sinovac Requests Extension for Annual Shareholders Meeting
5. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
6. Sinovac Closes $9.75 Million Private Placement
7. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
8. Sinovac Announces Adjournment of Annual General Meeting
9. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results
10. Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results
11. Sinovac Biotech Holds Annual General Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22. 2015  Varian Medical Systems (NYSE: VAR ), ... for its commitment to sustainability with inclusion on a prestigious ... highest ranked healthcare equipment company among the Corporate Knights Global ... Economic Forum at Davos, Switzerland . ...
(Date:12/24/2014)... Md. , Dec. 24, 2014  United Therapeutics Corporation ... Inc. (NYSE: MDT ) has submitted a ... Administration (FDA) for the use of Medtronic,s SynchroMed ® ... developed catheter) for use with United Therapeutics, Remodulin ® ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 “Preparative ... Gas, HPLC, Flash), Consumables (Columns, Solvents, Buffers, Valves, ... Food & Agriculture) - Forecasts to 2019” provides ... challenges, opportunities, current market trends, and strategies impacting ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 On Friday, ... 83, the Omnibus and Continuing Resolution Appropriations Act of ... condition eligible to receive funding through the Congressionally Directed ... Defense (DoD). The Hydrocephalus Association (HA), working in conjunction ...
Breaking Biology Technology:Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
... Minimal Effect on Heart Rhythm ... Changes in Schizophrenia Patients, VIENNA, Austria, Oct. 17 ... Organon -- is effective,in treating acute manic episodes associated with bipolar ... this week at,the 20th European College of Neuropsychopharmacology (ECNP) Congress. ...
... PRINCETON, N.J., Oct. 16 Bristol-Myers Squibb,Company (NYSE: ... Food and Drug,Administration (FDA) has granted approval of ... with metastatic or locally,advanced breast cancer in patients ... and capecitabine. The FDA has also granted,approval of ...
... Management Team, ROCKVILLE, Md., Oct. 16 ... company developing,therapeutics for the treatment of cancer and ... has been appointed its Senior Vice,President, Research and ... officer of EntreMed by the Board of Directors, ...
Cached Biology Technology:Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 2Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 3Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 4Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 5Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 6FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 2FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 3FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 4FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 5FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 6FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 7EntreMed Appoints Senior Vice President of Research and Development 2EntreMed Appoints Senior Vice President of Research and Development 3EntreMed Appoints Senior Vice President of Research and Development 4
(Date:1/22/2015)... EyeLock, Inc. , a market leader of iris-based identity authentication ... to the new role of Senior Vice President of Mobile ... mobile platforms and wearable solutions for EyeLock,s technologies. Gerber brings ... semiconductor industry to his role at EyeLock, with expertise in ...
(Date:12/24/2014)...  Since its launch in December 2014, the 1U™ ... of trying to remember their usernames and passwords through replacing ... smartphones. To assist people who have struggled to remember usernames ... 1U and focuses on redefining identity, announced today that it ...
(Date:12/22/2014)... 22, 2014 Research and Markets ( ... "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides ... and fingerprinting markets. Watermarking aims to control and ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3The Global Watermarking and Fingerprinting Markets 2
... of prostate cancer in mice and has beneficial effects on ... metabolism, UC Davis and the U.S. Department of Agriculture Western ... study, by Paul Davis, nutritionist in the Department of Nutrition ... the findings today at the annual national meeting of the ...
... Department of Energy (DOE) Joint Genome Institute (JGI) has ... 13th Annual Applied Ergonomics Conference held March 22-25, 2010 ... Improvement Initiatives category, the DOE JGI,s entry is "Empowering ... the DOE JGI program that help promote awareness of ...
... ESA,s TIGER II initiative has selected 20 project proposals ... learn more about the water cycle and to improve ... results and achievements of its precursor TIGER I, which ... to bridge Africa,s water information gap using Earth-observation (EO) ...
Cached Biology News:Walnuts slow prostate tumors in mice 2DOE JGI vying for 2010 Ergo Cup 2ESA's TIGER II to support 20 water projects in Africa 2ESA's TIGER II to support 20 water projects in Africa 3
... sensitive laser confocal systems designed for rapid ... that meet your expectations, differentiating between a ... the signal on the bottom as well ... for increased sensitivity. Results with VersArray ChipReader ...
Bio-Plex Manager software, version 3.0, 5 license netshare, is a five-user software package that provides access to data from the Bio-Plex suspension array system from a server. This version does not...
... System is an automated multiplexing platform that ... detection, pathogen sequence detection and pharmacogenetics applications. ... applied to an open and flexible electronic ... reused until all tests sites have been ...
... : GeneTraffic is built to be a ... GeneTraffic provides visual and computational tools to ... to analysis. , Data and Project ... the MIAME (Minimum Information About a Microarray ...
Biology Products: